15539 Background: Prostate cancer can be detrimental to bone health: it affects older men who have a higher risk of osteoporosis; common treatment is androgen ablation which can cause bone loss, and it frequently metastasizes to the bones. These issues are especially important in AA men, who present with higher rates of advanced disease and use of androgen ablation than whites. One study found beneficial effects of Z on the bone health of men with prostate cancer, it included only 106 men, and few were AA (Smith M, Journal of Urology).We wanted to evaluate the effects of Ca/Vitamin D ± Z on skeletal related events and BMD on AA and white men with prostate cancer who are receiving androgen ablation therapy. Methods: Prostate cancer patients receiving at least 3 months of androgen ablation were eligible. Exclusion criteria: use of bisphosphonates in last 12 months, abnormal liver/ kidney function, or prior bone disease. 41 patients have been randomized, 51% are AA. Patients on the Z arm receive 4 mg IV infusion of Z q 3 months over one year. Patients have bone densities at baseline and 13 months. Results: Interim analysis is available for patients who have completed study as of Jan 2007. 3 patients were taken off study (1 due to secondary cancer, 2 due to patient withdrawal).One patient withdrew due to jaw pain, follow up did not identify osteonecrosis. Two patients had lesions that may have been bone metastases, follow up testing was inconclusive. At treatment end, Z-treated patients had higher BMD scores than control group patients. AA patients treated with Z also showed increased BMD values at 13 months. Conclusions: Z appears to have a positive effect on BMD in AA men with prostate cancer- potentially more beneficial than among the effect previously reported for white men with prostate cancer. AA men with prostate cancer receiving androgen ablation should be considered for Z therapy to improve bone health. [Table: see text] No significant financial relationships to disclose.
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
